Skip to content
type1.science
ObservationalActive, not recruitingNCT04598893

PROTECT extension: long-term teplizumab safety

Extension study following recent-onset T1D participants treated in teplizumab PROTECT to track longer-term safety and disease-course signals.

Primary endpoints

  • Incidence of adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESIs), including infections and malignancies

Results so far

No results posted yet.